T. Sawanobori

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

S. Ito, M. Nangaku, K. Shikata, 2019, Clinical journal of the American Society of Nephrology : CJASN.

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.

S. Ito, M. Nangaku, N. Kashihara, 2020, Clinical journal of the American Society of Nephrology : CJASN.

Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study

S. Ito, M. Nangaku, T. Wada, 2021, Clinical and Experimental Nephrology.

Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies

S. Ito, M. Nangaku, T. Wada, 2022, Journal of diabetes investigation.

The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial

S. Ito, M. Nangaku, K. Shikata, 2022, Hypertension Research.

Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J‐RHYTHM Registry

T. Osaka, N. Hagiwara, T. Nakamura, 2016, Journal of the American Heart Association.

The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial

S. Ito, M. Nangaku, K. Shikata, 2022, Hypertension Research.